Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875651 · ClinicalTrials.gov registry record
A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 100
- Enrollment target
NCT03875651: Completed study, sponsored by Boston Scientific Corporation.
NCT03875651 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03875651 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of patients with coronary artery disease in large vessels (≤ 28 mm in length, by visual estimate, in native coronary arteries \> 4.00 mm to ≤5.00 mm in diameter, by visual estimate). This Post Approval study is a cohort associated with the SYNERGY MEGATRON Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT04807439.
Primary Outcome
12-month Target Lesion Failure (TLF) rate, defined as any ischemia driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.
Interventions
- DEVICE SYNERGY 4.50 mm and 5.0 mm Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2023-11-28 |
What the finished NCT03875651 record still lists
NCT03875651 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which SYNERGY 4.50 mm and 5.0 mm Coronary Stent System is the first listed.
NCT03875651 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03875651 about?
NCT03875651 is a clinical study titled "A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)". EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronary Stent System for the treatment of patients with coronary artery disease in large vessels (≤ 28 mm in length, b...
What is the current status of trial NCT03875651?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-05-09. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT03875651?
The interventions under investigation include: SYNERGY 4.50 mm and 5.0 mm Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT03875651?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI